Fundraising FoxHatch BioFund — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Latus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise.
AI & Machine LearningBiotechDeep TechHealthtechPhiladelphia, US
Co-investors8VCBioAdvanceDCVC (Data Collective)DCVC BioGaingelsKorea Development Bank+1 more
__Twitter.png)
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity.
BiotechDeep TechHealthtechPrinceton, US
Robert K. Prud'homme, PhD(Director)Bob Prud'homme(Leadership (PhD))Rob Pagels(Leadership (PhD))Chet Markwalter(Leadership (PhD))inShahram Hejazi(Leadership (PhD))inGregory Harriman(Leadership (MD))in
Co-investors7G BioVenturesAnzu Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.